CohBar, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CWBR research report →
Companywww.cohbar.com
CohBar, Inc. , a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease.
- CEO
- Pinchas Cohen Dean,
- IPO
- 2017
- Employees
- 9
- HQ
- Menlo Park, CA, US
Price Chart
Valuation
- Market Cap
- $1.19M
- P/E
- -0.10
- P/S
- 0.00
- P/B
- 0.08
- EV/EBITDA
- 0.39
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -58.44%
- ROIC
- -79.39%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-11,962,119 · 22.36%
- EPS
- $-4.13 · 40.49%
- Op Income
- $-12,388,297
- FCF YoY
- 27.74%
Performance & Tape
- 52W High
- $1.01
- 52W Low
- $0.00
- 50D MA
- $0.48
- 200D MA
- $0.54
- Beta
- 1.38
- Avg Volume
- 3.04K
Get TickerSpark's AI analysis on CWBR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 1, 22 | Biunno Jeffrey Francis | other | 26,203 |
| Aug 1, 22 | Sarret Joseph J. | other | 131,017 |
| Jul 11, 22 | Tozzo Stephanie | other | 200,000 |
| Jul 11, 22 | Tozzo Stephanie | other | 0 |
| Dec 29, 21 | Biunno Jeffrey Francis | other | 75,000 |
| Dec 29, 21 | Sarret Joseph J. | other | 650,000 |
| Nov 1, 21 | GREENWOOD DAVID | buy | 20,000 |
| Nov 1, 21 | GREENWOOD DAVID | buy | 20,000 |
| Nov 1, 21 | Barzilai Nir Yacov | buy | 13,889 |
| Nov 1, 21 | Barzilai Nir Yacov | buy | 13,889 |
Our CWBR Coverage
We haven't published any research on CWBR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CWBR Report →